SARS-CoV-2 Infection and Antiviral Strategies: Advances and Limitations
Viruses · 30.07.2025 · 17 (8) · 1064
DOI: 10.3390/v17081064 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 30.07.2025. Verfasst von Vinicius Cardoso Soares und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro 21040-361, Brazil. Hauptthemen laut MEDLINE: Antiviral Agents, SARS-CoV-2, COVID-19 Drug Treatment. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Since the onset of the COVID-19 pandemic, remarkable progress has been made in the development of antiviral therapies for SARS-CoV-2. Several direct-acting antivirals, such as remdesivir, molnupiravir, and nirmatrelvir/ritonavir, offer clinical benefits. These agents have significantly contributed to reducing the viral loads and duration of the illness, as well as the disease’s severity and mortality. However, despite these advances, important limitations remain. The continued emergence of resistant SARS-CoV-2 variants highlights the urgent need for adaptable and durable therapeutic strategies. Therefore, this review aims to provide an updated overview of the main antiviral strategies that are used and the discovery of new drugs against SARS-CoV-2, as well as the therapeutic limitations that have shaped clinical management in recent years. The major challenges include resistance associated with viral mutations, limited treatment windows, and unequal access to treatment. Moreover, there is an ongoing need to identify novel compounds with broad-spectrum activity, improved pharmacokinetics, and suitable safety profiles. Combination treatment regimens represent a promising strategy to increase the efficacy of treating COVID-19 while minimizing the potential for resistance. Ideally, these interventions should be safe, affordable, and easy to administer, which would ensure broad global access and equitable treatment and enable control of COVID-19 cases and preparedness for future threats.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro 21040-361, Brazil.
- Center for Research, Innovation and Surveillance in COVID-19 and Health Emergencies, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro 21040-361, Brazil.
- Program of Immunology and Inflammation, Federal University of Rio de Janeiro UFRJ, Rio de Janeiro 21941-902, Brazil.
ORCID-Profile: Vinicius Cardoso Soares, Isabela Batista Gonçalves Moreira, Suelen Silva Gomes Dias
Zitieren
APA
Soares, V. C., Moreira, I. B. G., & Dias, S. S. G. (2025). SARS-CoV-2 Infection and Antiviral Strategies: Advances and Limitations. Viruses, 17(8), 1064. https://doi.org/10.3390/v17081064
Vancouver
Soares VC, Moreira IBG, Dias SSG. SARS-CoV-2 Infection and Antiviral Strategies: Advances and Limitations. Viruses. 2025;17(8):1064. doi:10.3390/v17081064
BibTeX
@article{Soares2025,
author = {Soares, Vinicius Cardoso and Moreira, Isabela Batista Gonçalves and Dias, Suelen Silva Gomes},
title = {SARS-CoV-2 Infection and Antiviral Strategies: Advances and Limitations},
journal = {Viruses},
year = {2025},
volume = {17},
number = {8},
pages = {1064},
doi = {10.3390/v17081064}
}
EUVIMED